This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dong, S. M. Articles by Sidransky, D. Search for Related Content PubMed PubMed Citation Articles by Dong, S. M. Articles by Sidransky, D.

Promoter Hypermethylation of Multiple Genes in Carcinoma of the Uterine Cervix¹

Department of Otolaryngology-Head and Neck Surgery, Head and Neck Cancer Research Division, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205-2196 [S. M. D., S-H. R., D. S.]; Department of Pathology, Samsung Cheil Hospital, Sungkyunkwan University School of Medicine, Seoul 100-380, Korea [H-S. K.]; and Department of Pathology, Dong-A University College of Medicine, Pusan 602-103, Korea [S-H. R.]

	ABSTRACT

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Promoter hypermethylation is an important pathway for the repression of gene transcription in cancer. We investigated promoter hypermethylation of six genes, p16, APC, HIC-1, death-associated protein kinase (DAPK), O⁶-methylguanine-DNA-methyltransferase (MGMT), and E-cadherin, in uterine cervical carcinoma from 53 patients including 31 cases of squamous cell carcinoma (SCC) and 22 cases of adenocarcinoma (AC). Aberrant methylation of at least one of these genes was detected in 79% (42 of 53) of cases including 71% (22 of 31) of SCC and 91% (20 of 22) of AC cases. No aberrant methylation was detected in normal cervical tissue from 24 control hysterectomy specimens. There was no correlation between promoter hypermethylation at any gene and the presence of human papillomavirus-16 or -18 E7 DNA. In AC cases, promoter hypermethylation of the APC and HIC-1 genes was detected at a statistically significant higher frequency than in the SCC cases (APC, 60% versus 13%, P < 0.001; HIC-1, 63% versus 32%, P < 0.03). Conversely, promoter hypermethylation of p16 and DAPK was more common in SCC cases than in AC cases. Our results suggest that promoter hypermethylation is a frequent epigenetic event in cervical carcinoma. The pattern of gene promoter hypermethylation is distinctly different between AC and SCC. The absence of these epigenetic alterations in normal cervical tissue suggests that they may also be valuable as cancer markers.

	INTRODUCTION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Cancer of the cervix is the second most common cancer in women worldwide (1) . Multiple epidemiological studies indicate that HPV³ infection is frequently detected in cervical intraepithelial neoplasia and invasive cervical carcinoma (2) . There is a strong association between certain subtypes of the HPV and cervical carcinoma (3) . The E6 and E7 genes of oncogenic HPV-16 and -18 are known to play an important role in the early stages of malignant transformation and immortalization of cervical epithelial cells (3, 4, 5) . Inactivation of the p53 and Rb gene products by the E6 and E7 proteins, respectively, is an important process in maintaining abnormal cellular proliferation by inactivating normal cell cycle checkpoints (5, 6, 7) . In addition to HPV infection, it is clear that other factors are also involved in cervical carcinogenesis because the majority of patients with HPV-associated lesions do not progress to invasive cancer. Therefore, it is important to identify other genetic and epigenetic events in cervical carcinogenesis.

In the development of cancer, tumor suppressor genes are inactivated by a number of processes including point mutation and chromosomal deletion. Numerous studies have reported loss of heterozygosity in different chromosomal regions, suggesting the common inactivation of tumor suppressor genes in cervical carcinoma (8, 9, 10, 11) . In addition to chromosomal deletions, epigenetic silencing of tumor suppressor genes by promoter hypermethylation is also commonly seen in human cancer (12) . Aberrant methylation of CpG islands within the promoter regions of tumor suppressor genes such as p16, VHL, E-cadherin, APC, and hMLH1 has been identified in association with loss of protein expression in cancer cells (13, 14, 15, 16, 17) . Several tumor types have also shown aberrant methylation at CpG islands in other genes, including the DNA repair gene O⁶-methylguanine-DNA methyltransferase (MGMT; Ref. 18 ), the potential metastasis inhibitor gene death-associated kinase (DAPK; Ref. 19 ), and the candidate tumor suppressor HIC-1 (20) .

On the basis of these observations, we examined the promoter methylation status of the p16, DAPK, MGMT, APC, HIC-1, and E-cadherin genes in uterine cervical carcinoma and normal cervical tissues from patients without cancer using the MSP approach. We found frequent promoter hypermethylation of these genes related to tumor histology, but we did not found an association of methylation status with HPV infection.

	MATERIALS AND METHODS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Sample Collection and DNA Extraction.
Fifty-three tumor samples were collected from cases of invasive cervical carcinoma resected at the Samsung Cheil Hospital (Seoul, Korea) with institutional review board approval. There were 31 SCCs and 22 ACs. Twenty-four control samples of normal cervical hysterectomy specimens from patients without cancer at this institution were also analyzed. The histological type and grade of tumors were classified according to the WHO criteria. The stage of each cancer was established according to the International Federation of Gynecology and Obstetrics criteria. Paraffin-embedded primary tumor tissue and control samples were prepared from H&E-stained 10-µm-section slides. Tumor tissue was selected from an area with >75% malignant cells. DNA was purified by phenol-chloroform extraction and ethanol precipitation and dissolved in 50 µl of distilled water as described previously (21) .

Bisulfite Modification.
One µg of genomic DNA was denatured with NaOH. The bisulfite treatment (during which methylated DNA is protected, and unmethylated cytosine is conversed to uracil) was carried out for 16 h at 50°C on denatured genomic DNA as described by Herman et al. (22) . DNA samples were then purified using the Wizard DNA Clean-Up System (Promega, Madison, WI), treated again with NaOH, ethanol-precipitated, and resuspended in water.

MSP and Direct Sequencing.
The modified DNA was used as a template for MSP using primers specific for either the methylated or the modified unmethylated sequences (22) . Appropriate negative and positive controls were included in each PCR reaction. Primer sequences for the p16 (22) , MGMT (18) , DAPK (19) , and E-cadherin (22) genes were described previously. The primer sequences of HIC-1 gene promoter for the unmethylated reaction were 5'-TTGGGTTTGGTTTTTGTGTTTTG-3' (sense) and 5'-CACCCTAACACCACCCTAAC-3' (antisense), which amplify a 118-bp product. The primer sequences of HIC-1 gene promoter for the methylated reaction were 5'-TCGGTTTTCGCGTTTTGTTCGT-3' (sense) and 5'-AACCGAAAACTATCAACCCTCG-3' (antisense), which amplify a 95-bp product. The 5' position of the sense unmethylated and methylated primers corresponds to bp 20 and 26 of GenBank accession number L41919, respectively, and -617 and -611 relative to the HIC-1 major transcription start site, respectively. The primer sequences of APC gene promoter 1A for the unmethylated reaction were 5'-AATTTGTTGGATGTGGATTAGGGT-3' (sense) and 5'-AACCTCATATCAATCACATACA-3' (antisense), which amplify a 89-bp product, and the primer sequences of APC gene promoter 1A for the methylated reaction were 5'-CGTTGGATGCGGATTAGGGC-3' (sense) and 5'-CCTCATATCGATCACGTACG-3' (antisense), which amplify a 84-bp product. The 5' position of the sense unmethylated and methylated primers corresponds to bp 748 and 751 of GenBank accession number U02509, respectively, and -118 and -115 relative to the APC major transcription start site, respectively.

Step-down PCR reactions were performed in a 25 µl reaction volume, using previously published conditions (22) and 1.25 units of Ampli Taq polymerase (Perkin-Elmer, Branchburg, NJ) complexed with Taq start antibody (Clontech, Palo Alto, CA). Reactions were hot-started at 95°C for 5 min. This was followed by 30 cycles of 95°C for 30 s, 60°C for 30 s, and 72°C for 30 s and concluded at 72°C for 5 min. Reactions were analyzed on Spreadex EL 400 gels in the SEA 2000 Apparatus System (Elchrom Scientific, Charm, Switzerland), stained with SYBR Gold (Molecular Probes, Eugene, OR), and visualized under UV illumination.

After detection of a PCR product with methylated primers for APC and HIC-1, direct PCR sequencing reactions were performed on four samples using the Amplicycle Sequencing Kit (Perkin-Elmer). We used two cases of AC and two cases of SCC. For the direct sequence analysis, in four of four cases, all of the CpG sites (11 of APC and 15 of HIC-1) in each amplified segment were found to be methylated (data not shown).

HPV E7 Type-specific PCR.
Purified genomic DNA was amplified by PCR for the HPV-16 and HPV-18 E7 genes as well as for an internal reference gene, ß-globin. Oligonucleotide primers were as follows: (a) HPV-16 E7, forward primer 5'-ATTAAATGACAGCTCAGAGGA-3' and reverse primer 5'-GCTTTGTACGCACAACCGAAGC 3'; (b) HPV-18 E7, forward primer 5'-AAGAAAACGATGAAATAGATGGA 3' and reverse primer 5'-GGCTTCACACTTACAACACA-3'; and (c) ß-globin, forward primer 5'-GAAGAGCCAAGGACAGGTAC-3' and reverse primer 5'-CAACTTCATCCACGTTCACC-3'. DNA made from confluent culture of the human cervical carcinoma cell lines CaSki (HPV-16) and HeLa (HPV-18; American Type culture Collection, Manassas, VA) was used as a positive control.

Each PCR reaction was performed under standard conditions in a total volume of 20 µl containing 5 µl of template DNA, 2.5 µM each primer, 50 µM deoxynucleotide triphosphate, 3.75 mM MgCl₂, 1.25 units of Ampli Taq Gold (Perkin-Elmer), and 2 µl of 10x PCR Gold Buffer (Perkin-Elmer). Reactions were denatured for 10 min at 95°C and incubated for 40 cycles (95°C for 30 s, 55°C for 1 min, and 72°C for 1 min, followed by 10 min at 72°C). The reaction product was analyzed using the same system used in MSP.

Statistical Analysis.
Statistical analyses were performed using SigmaStat program 1.02. The associations between the discrete variables were assessed using Fisher’s exact test. Differences were considered statistically significant for P < 0.05.

	RESULTS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
We searched for the presence of promoter hypermethylation at six genes (p16, APC, HIC-1, DAPK, MGMT, and E-cadherin) in cervical cancer and normal tissue (Fig. 1) . Aberrant promoter hypermethylation at any of these genes studied was detected in 79% (42 of 53) of cervical carcinoma cases. These alterations were detected in 91% (20 of 22) of AC cases and 71% (22 of 31) of SCC cases (Table 1) . Promoter hypermethylation of p16 was detected in 30% (16 of 53) of all cases, and DAPK promoter hypermethylation was very common in SCC [61% (19 of 31)]. APC promoter hypermethylation was detected in 32% (17 of 53) of all cases including 13 of 22 (59%) AC cases. HIC-1 promoter hypermethylation was present in 45% (24 of 53) of all cases and was also very frequent [64% (14 of 22)] in AC cases. MGMT promoter hypermethylation and E-cadherin promoter hypermethylation were less common (Table 1) . Promoter hypermethylation of the p16 and DAPK genes was detected more frequently in SCC cases than in AC cases (p16, 39% versus 18%; DAPK, 61% versus 36%; P < 0.05). In AC cases, promoter hypermethylation of the APC and HIC-1 genes was detected at a significantly higher frequency than in the SCC cases [APC, 60% versus 13% (P < 0.001); HIC-1, 63% versus 32% (P < 0.03)]. None of the 24 normal cervical tissues demonstrated methylation at any gene.

View larger version (96K): [in this window] [in a new window]   Fig. 1. Gene promoter hypermethylation in uterine cervical carcinoma. MW, molecular weight DNA marker. A visible PCR product in Lane U indicates the presence of unmethylated gene promoters; the presence of product in Lane M indicates the presence of promoter methylation sequences. In each case, DNA from normal cervical epithelial tissue (NT) was used as a negative control, and in vitro methylated DNA (IVD) was used as a positive control for methylation. A water (H2O) only reaction was also used as a negative PCR control.

	DISCUSSION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

DNA methylation is an epigenetic modification essential to mammalian development. However, aberrations in DNA methylation including widespread hypomethylation and more focal hypermethylation have been consistently detected in human tumor and transformed cell lines (30, 31, 32) . Hypermethylation of normally unmethylated CpG islands in the promoter regions often occurs in important tumor suppressor genes such as VHL, hMLH1, E-cadherin, APC, and p16 (13, 14, 15, 16, 17) . This study is among the first general surveys of promoter hypermethylation in cervical carcinoma. Wong et al. (33) evaluated 98 cervical carcinomas and detected methylation of p16 in 31% of tumors. In a study by Nuovo et al. (34) , hypermethylation-induced inactivation of the p16 gene was reported as an early event in uterine cervical carcinoma. Recently, promoter hypermethylation has been identified and associated with loss of expression of many potentially interesting genes in cancer cells. These include the DNA repair gene MGMT, which is frequently inactivated in lymphoma and brain, colorectal, and lung cancers (19) ; the potential metastasis inhibitor DAPK gene altered in lymphoma, leukemia, and lung cancer (19 , 35) ; and the candidate tumor suppressor HIC-1 gene inactivated in leukemia and breast cancer (36 , 37) .

Here, we analyzed the methylation pattern of promoter regions of six tumor-related genes in the same cohort of cervical carcinoma patients using MSP. Promoter hypermethylation was seen most commonly in DAPK and HIC-1 and less commonly in the other tested genes. Overall, 79% of cervical tumors showed promoter hypermethylation at one or more genes. Moreover, hypermethylation was not limited to a single target but was often found in multiple genes in each patient studied. Interestingly, the subset of genes methylated varied in each patient. In fact, 33 of 53 (62%) cervical cancers displayed concordant methylation in at least two genes, and 9 of 53 (17%) cervical cancers harbored hypermethylation status in only one gene. It is clear that aberrant hypermethylation of promoter regions is not confined to a single target gene in cervical carcinoma but rather occurs concurrently in many loci (including untested genes) in an individual patient.

By studying the methylation profile of several target genes for the AC and SCC subtypes of cervical carcinoma, we found that methylation of p16 and DAPK was detected in AC at a lower frequency than in SCC (Table 1) , whereas promoter hypermethylation of APC and HIC-1 was present at a significantly higher frequency in AC than in SCC (Table 1) . The pattern of promoter hypermethylation is distinctly different between AC and SCC of the cervix, suggesting a distinct pathway of progression for these different tumor types. Epigenetic silencing of p16 leads to absence of the protein and is analogous to homozygous deletion and/or point mutation providing the cell with a selective growth advantage (13) . Because Rb and p16 inactivations are inversely correlated in most tumor types, it is tempting to speculate that HPV infection provides an additional growth advantage predominantly by inactivation of p53 through the E6 protein. Although we could not test for RNA expression directly in these paraffin-embedded tissues, it is likely that promoter hypermethylation of the other genes tested also led to inactivation of critical pathways as described previously in cell lines and fresh tumors (12, 13, 14, 15 , 18 , 19 , 35 , 38) . In this study, we have demonstrated that promoter hypermethylation (often with HPV infection) is a frequent epigenetic event in cervical carcinoma. The fact that multiple genes are frequently methylated suggests that the mechanism that normally protects CpG islands from methylation may be defective in cancer cells. The epigenetic alterations found in our cancer cases were absent in normal tissue, suggesting that they may also be useful as cancer-specific markers (19 , 39, 40, 41, 42) .

	FOOTNOTES

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported by Grants P01-CA-98-028 and U01-CA-84986. Funding for the study described in this article was provided by Virco, Inc. Under a licensing agreement between The Johns Hopkins University and Virco, D. S. is entitled to a share of royalty received by the University on sales or products described in this article. The University and D. S. own Virco stock, which is subject to certain restrictions under University policy. D. S. is a paid consultant to Virco. The terms of this arrangement are being managed by The Johns Hopkins University in accordance with its conflict of interest policies.

² To whom requests for reprints should be addressed, at Department of Otolaryngology-Head and Neck Surgery, Division of Head and Neck Cancer Research, The Johns Hopkins University School of Medicine, 818 Ross Research Building, 720 Rutland Avenue, Baltimore, MD 21205-2196. Phone: (410) 502-5153; Fax: (410) 614-1411; E-mail: dsidrans@jhmi.edu.

³ The abbreviations used are: HPV, human papillomavirus; SCC, squamous cell carcinoma; AC, adenocarcinoma; MSP, methylation-specific PCR.

Received 12/ 6/00; revised 3/26/01; accepted 3/27/01.

	REFERENCES

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 

1. Cervical Cancer. NIH Consensus Statement, Vol. 14, pp. 1–38. Bethesda, MD: NIH, 1996.
2. Bosch F. X., Manos M. M., Munoz N., Sherman M., Jansen A. M., Peto J., Schiffman M. H., Moreno V., Kurman R., Shah K. V. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J. Natl. Cancer Inst. (Bethesda), 87: 796-802, 1995.[Abstract/Free Full Text]
3. zur Hausen H. Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers. Cancer Res., 49: 4677-4681, 1989.[Abstract/Free Full Text]
4. Lorincz A. T., Reid R., Jenson A. B., Greenberg M. D., Lancaster W., Kurman R. J. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogeital types. Obstet. Gynecol., 79: 328-337, 1992.[Medline]
5. Woodworth C. D., Doniger J., DiPaola J. A. Immortalization of human keratinocytes by various human papillomavirus DNAs corresponds to their association with cervical carcinoma. J. Virol., 63: 159-164, 1989.[Abstract/Free Full Text]
6. Werness B. A., Levine A. J., Howley P. M. Association of human papillomavirus type 16 and 18 E6 protein with p53. Science (Wash. DC), 248: 76-79, 1990.[Abstract/Free Full Text]
7. Scheffner M., Munger K., Byrne J. C., Howley P. M. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl. Acad. Sci. USA, 88: 5523-5527, 1991.[Abstract/Free Full Text]
8. Wistuba I. I., Montellano F. D., Milchgrub S., Virmani A. K., Behrens C., Chen H., Ahmadian M., Nowak J. A., Muller C., Minna J. D., Gazdar A. F. Deletions of chromosome 3p are frequent and early events in the pathogenesis of uterine cervical carcinoma. Cancer Res., 57: 3154-3158, 1997.[Abstract/Free Full Text]
9. Mitra A. B., Murty V. V., Singh V., Li R. G., Pratap M., Sodhani P., Luthra U. K., Chaganti R. S. Genetic alteration at 5p15: a potential marker for progression of precancerous lesions of the uterine cervix. J. Natl. Cancer Inst. (Bethesda), 87: 742-745, 1995.[Abstract/Free Full Text]
10. Rader J. S., Kamarasova T., Huettner P. C., Li L., Li Y., Gerhard D. S. Allelotyping of all chromosomal arms in invasive cervical cancer. Oncogene, 13: 2737-2741, 1996.[Medline]
11. Hampton G. M., Penny L. A., Baergen R. N., Larson A., Brewer C., Liao S., Busby-Earle R. M. C., Williams A. W. R., Steel C. M., Bird C. C., Stanbridge E. J., Evans G. A. Loss of heterozygosity in cervical carcinoma: subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22–q24. Proc. Natl. Acad. Sci. USA, 91: 6953-6957, 1994.[Abstract/Free Full Text]
12. Baylin S. B., Herman J. G., Graff J. R., Vertino P. M., Issa J. P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res., 72: 141-196, 1998.[Medline]
13. Merlo A., Herman J. G., Mao L., Lee D. J., Gabrielson E., Burger P. C., Baylin S. B., Sidransky D. 5' CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med., 1: 686-692, 1995.[CrossRef][Medline]
14. Herman J. G., Latif F., Weng Y., Lerman M. I., Zbar B., Liu S., Samid D., Duan D. R., Gnarra J. R., Linehan W. M., Baylin S. B. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. USA, 91: 9700-9704, 1994.[Abstract/Free Full Text]
15. Herman J. G., Umar A., Polyak K., Graff J. R., Ahuja N., Issa J. P., Markowitz S., Wilson J. K. V., Hamilton S. R., Kinzler K. W., Kane M. F., Kolodner R. D., Volgelstein B., Kunkel T. A., Baylin S. B. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA, 95: 6870-6875, 1998.[Abstract/Free Full Text]
16. Esteller M., Sparks A., Toyota M., Sanchez-Cespedes M., Capella G., Peinado M. A., Gonzalez S., Tarafa G., Sidransky D., Meltzer S. J., Baylin S. B., Herman J. G. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res., 60: 4366-4371, 2000.[Abstract/Free Full Text]
17. Graff J. R., Herman J. G., Lapidus R. G., Chopra H., Xu R., Jarrard D. F., Isaacs W. B., Pitha P. M., Davidson N. E., Baylin S. B. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res., 55: 5195-5199, 1995.[Abstract/Free Full Text]
18. Esteller M., Hamilton S. R., Burger P. C., Baylin S. B., Herman J. G. Inactivation of the DNA repair gene O⁶-methylguanine-DNA-methyltrasferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res., 59: 793-797, 1999.[Abstract/Free Full Text]
19. Esteller M., Sanchez-Cespedes M., Rosell R., Sidransky D., Baylin S. B., Herman J. G. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res., 59: 67-70, 1999.[Abstract/Free Full Text]
20. Issa J. P., Zehnbauer B. A., Kaufman S. H., Biel M. A., Baylin S. B. HIC1 hypermethyaltion is a late event in hematopoietic neoplasms. Cancer Res., 57: 1678-1681, 1997.[Abstract/Free Full Text]
21. Nawroz H., Koch W., Anker P., Stroun M., Sidransky D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat. Med., 2: 1035-1037, 1996.[CrossRef][Medline]
22. Herman J. G., Graff J. R., Myohanen S., Nelkin B. D., Baylin S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA, 93: 9821-9826, 1996.[Abstract/Free Full Text]
23. Cuzick J., Terry G., Ho L., Monaghan J., Lopes A., Clarkson P., Duncan I. Association between high-risk HPV types, HLA DRB1* and DQB1* alleles and cervical cancer in British women. Br. J. Cancer, 82: 1348-1352, 2000.[CrossRef][Medline]
24. Averette H. E., Steren A., Nguyen H. N. Screening in gynecologic cancers. Cancer (Phila.), 72: 1043-1049, 1993.[CrossRef][Medline]
25. Cullen A. P., Reid R., Campion M., Lorincz A. T. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J. Virol., 65: 606-612, 1991.[Abstract/Free Full Text]
26. Snijders P. J., Meijer C. J., van den Brule A. J. C., Schrijnemarkers H. F., Snow G. B., Walboomers J. M. M. Human papillomavirus (HPV) type 16 and 33 E6/E7 transcripts in tonsillar carcinomas can originate from integrated and episomal HPV DNA. J. Gen. Virol., 73: 2059-2066, 1992.[Abstract/Free Full Text]
27. Boshart M., Gissmann L., Ikenberg H., Kleinheinz A., Scheurlen W., zur Hausen H. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J., 3: 1151-1157, 1984.[Medline]
28. Durst M., Gissmann L., Ikenberg H., zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc. Natl. Acad. Sci. USA, 80: 3812-3815, 1983.[Abstract/Free Full Text]
29. Fearon E. R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell, 61: 759-767, 1990.[CrossRef][Medline]
30. Goelz S. E., Vogelstein B., Hamilton S. R., Feinberg A. P. Hypomethylation of DNA from benign and malignant human colon neoplasms. Science (Wash. DC), 228: 187-190, 1985.[Abstract/Free Full Text]
31. Feinberg A. P., Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature (Lond.), 301: 89-92, 1983.[CrossRef][Medline]
32. de Bustros A., Nelkin B. D., Silverman A., Ehrlich G., Poiesz B., Baylin S. B. The short arm of chromosome 11 is a "hot spot" for hypermethylation in human neoplasia. Proc. Natl. Acad. Sci. USA, 85: 5693-5697, 1988.[Abstract/Free Full Text]
33. Wong Y. F., Chung T. K., Cheung T. H., Nobori T., Yu A. L., Yu J., Batova A., Lai K. W., Chang A. M. Methylation of p16^INK4A in primary gynecologic malignancy. Cancer Lett., 136: 231-235, 1999.[CrossRef][Medline]
34. Nuovo G. J., Plaia T. W., Belinsky S. A., Baylin S. B., Herman J. G. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc. Natl. Acad. Sci. USA, 96: 12754-12759, 1999.[Abstract/Free Full Text]
35. Katzenellenbogen R. A., Baylin S. B., Herman J. G. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood, 93: 4347-4353, 1999.[Abstract/Free Full Text]
36. Melki J. R., Vincent P. C., Clark S. J. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res., 59: 3730-3740, 1999.[Abstract/Free Full Text]
37. Fujii H., Biel M. A., Zhou W., Weitzman S. A., Baylin S. B., Gabrielson E. Methylation of the HIC-1 candidate tumor suppressor gene in human breast cancer. Oncogene, 16: 2159-2164, 1998.[CrossRef][Medline]
38. Graff J. R., Herman J. G., Myohanen S., Baylin S. B., Vertino P. M. Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation. J. Biol. Chem., 272: 22322-22329, 1997.[Abstract/Free Full Text]
39. Ahrendt S. A., Chow J. T., Xu L. H., Yang S. C., Eisenberger C. F., Esteller M., Herman J. G., Wu L., Decker P. A., Jen J., Sidransky D. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J. Natl. Cancer Inst. (Bethesda), 91: 332-339, 1999.[Abstract/Free Full Text]
40. Belinsky S. A., Nikula K. J., Palmisano W. A., Michels R., Saccomanno G., Gabrielson E., Baylin S. B., Herman J. G. Aberrant methylation of p16^INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl. Acad. Sci. USA, 95: 11891-11896, 1998.[Abstract/Free Full Text]
41. Sanchez-Cespedes M., Esteller M., Wu L., Nawroz-Danish H., Yoo G. H., Koch W. M., Jen J., Herman J. G., Sidransky D. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res., 60: 892-895, 2000.[Abstract/Free Full Text]
42. Rosas S. L., Koch W., da Costa Carvalho M. G., Wu L., Califano J., Westra W., Jen J., Sidransky D. Promoter hypermethylation patterns of p16, MGMT, and DAPK in tumor and saliva of head and neck cancer patients. Cancer Res., 61: 939-942, 2001.[Abstract/Free Full Text]

This article has been cited by other articles:

				S. S. Wang, D. J. Smiraglia, Y.-Z. Wu, S. Ghosh, J. S. Rader, K. R. Cho, T. A. Bonfiglio, R. Nayar, C. Plass, and M. E. Sherman Identification of Novel Methylation Markers in Cervical Cancer Using Restriction Landmark Genomic Scanning Cancer Res., April 1, 2008; 68(7): 2489 - 2497. [Abstract] [Full Text] [PDF]

				Y. Kanai and S. Hirohashi Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state Carcinogenesis, December 1, 2007; 28(12): 2434 - 2442. [Abstract] [Full Text] [PDF]

				J. K. Stephen, L. E. Vaught, K. M. Chen, V. Shah, V. G. Schweitzer, G. Gardner, M. S. Benninger, and M. J. Worsham An Epigenetically Derived Monoclonal Origin for Recurrent Respiratory Papillomatosis Arch Otolaryngol Head Neck Surg, July 1, 2007; 133(7): 684 - 692. [Abstract] [Full Text] [PDF]

				Q. Yang, C. M. Kiernan, Y. Tian, H. R. Salwen, A. Chlenski, B. A. Brumback, W. B. London, and S. L. Cohn Methylation of CASP8, DCR2, and HIN-1 in Neuroblastoma Is Associated with Poor Outcome Clin. Cancer Res., June 1, 2007; 13(11): 3191 - 3197. [Abstract] [Full Text] [PDF]

				C. Zhang, Z. Li, Y. Cheng, F. Jia, R. Li, M. Wu, K. Li, and L. Wei CpG Island Methylator Phenotype Association with Elevated Serum {alpha}-Fetoprotein Level in Hepatocellular Carcinoma Clin. Cancer Res., February 1, 2007; 13(3): 944 - 952. [Abstract] [Full Text] [PDF]

				M. D. Williams, N. Chakravarti, M. S. Kies, S.-I. Maruya, J. N. Myers, J. C. Haviland, R. S. Weber, R. Lotan, and A. K. El-Naggar Implications of Methylation Patterns of Cancer Genes in Salivary Gland Tumors Clin. Cancer Res., December 15, 2006; 12(24): 7353 - 7358. [Abstract] [Full Text] [PDF]

				V. V. Murty and G. Narayan Re: Detection of Hypermethylated Genes in Women With and Without Cervical Neoplasia J Natl Cancer Inst, October 19, 2005; 97(20): 1548 - 1548. [Full Text] [PDF]

				J. M. Teodoridis, J. Hall, S. Marsh, H. D. Kannall, C. Smyth, J. Curto, N. Siddiqui, H. Gabra, H. L. McLeod, G. Strathdee, et al. CpG Island Methylation of DNA Damage Response Genes in Advanced Ovarian Cancer Cancer Res., October 1, 2005; 65(19): 8961 - 8967. [Abstract] [Full Text] [PDF]

				M. O. Hoque, O. Topaloglu, S. Begum, R. Henrique, E. Rosenbaum, W. Van Criekinge, W. H. Westra, and D. Sidransky Quantitative Methylation-Specific Polymerase Chain Reaction Gene Patterns in Urine Sediment Distinguish Prostate Cancer Patients From Control Subjects J. Clin. Oncol., September 20, 2005; 23(27): 6569 - 6575. [Abstract] [Full Text] [PDF]

				J. Zhang, C. R. Martins, Z. B. Fansler, K. L. Roemer, E. A. Kincaid, K. S. Gustafson, D. F. Heitjan, and D. P. Clark DNA Methylation in Anal Intraepithelial Lesions and Anal Squamous Cell Carcinoma Clin. Cancer Res., September 15, 2005; 11(18): 6544 - 6549. [Abstract] [Full Text] [PDF]

				A. Uren, S. Fallen, H. Yuan, A. Usubutun, T. Kucukali, R. Schlegel, and J. A. Toretsky Activation of the Canonical Wnt Pathway during Genital Keratinocyte Transformation: A Model for Cervical Cancer Progression Cancer Res., July 15, 2005; 65(14): 6199 - 6206. [Abstract] [Full Text] [PDF]

				N Murphy, M Ring, C C B B Heffron, B King, A G Killalea, C Hughes, C M Martin, E McGuinness, O Sheils, and J J O'Leary p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer J. Clin. Pathol., May 1, 2005; 58(5): 525 - 534. [Abstract] [Full Text] [PDF]

				C D E Margetts, D Astuti, D C Gentle, W N Cooper, A Cascon, D Catchpoole, M Robledo, H P H Neumann, F Latif, and E R Maher Epigenetic analysis of HIC1, CASP8, FLIP, TSP1, DCR1, DCR2, DR4, DR5, KvDMR1, H19 and preferential 11p15.5 maternal-allele loss in von Hippel-Lindau and sporadic phaeochromocytomas Endocr. Relat. Cancer, March 1, 2005; 12(1): 161 - 172. [Abstract] [Full Text] [PDF]

				Q. Feng, A. Balasubramanian, S. E. Hawes, P. Toure, P. S. Sow, A. Dem, B. Dembele, C. W. Critchlow, L. Xi, H. Lu, et al. Detection of Hypermethylated Genes in Women with and Without Cervical Neoplasia J Natl Cancer Inst, February 16, 2005; 97(4): 273 - 282. [Abstract] [Full Text] [PDF]

				C. M. Lewis, L. R. Cler, D.-W. Bu, S. Zochbauer-Muller, S. Milchgrub, E. Z. Naftalis, A. M. Leitch, J. D. Minna, and D. M. Euhus Promoter Hypermethylation in Benign Breast Epithelium in Relation to Predicted Breast Cancer Risk Clin. Cancer Res., January 1, 2005; 11(1): 166 - 172. [Abstract] [Full Text] [PDF]

				W.-C. Xue, K. Y.K. Chan, H.-C. Feng, P.-M. Chiu, H. Y.S. Ngan, S.-W. Tsao, and A. N.Y. Cheung Promoter Hypermethylation of Multiple Genes in Hydatidiform Mole and Choriocarcinoma J. Mol. Diagn., November 1, 2004; 6(4): 326 - 334. [Abstract] [Full Text] [PDF]

				P. Parrella, M. L. Poeta, A. P. Gallo, M. Prencipe, M. Scintu, A. Apicella, R. Rossiello, G. Liguoro, D. Seripa, C. Gravina, et al. Nonrandom Distribution of Aberrant Promoter Methylation of Cancer-Related Genes in Sporadic Breast Tumors Clin. Cancer Res., August 15, 2004; 10(16): 5349 - 5354. [Abstract] [Full Text] [PDF]

				E. Dulaimi, I. I. de Caceres, R. G. Uzzo, T. Al-Saleem, R. E. Greenberg, T. J. Polascik, J. S. Babb, W. E. Grizzle, and P. Cairns Promoter Hypermethylation Profile of Kidney Cancer Clin. Cancer Res., June 15, 2004; 10(12): 3972 - 3979. [Abstract] [Full Text] [PDF]

				A. Widschwendter, C. Gattringer, L. Ivarsson, H. Fiegl, A. Schneitter, A. Ramoni, H. M. Muller, A. Wiedemair, S. Jerabek, E. Muller-Holzner, et al. Analysis of Aberrant DNA Methylation and Human Papillomavirus DNA in Cervicovaginal Specimens to Detect Invasive Cervical Cancer and Its Precursors Clin. Cancer Res., May 15, 2004; 10(10): 3396 - 3400. [Abstract] [Full Text] [PDF]

				N. Reesink-Peters, G. B. A. Wisman, C. Jeronimo, C. Y. Tokumaru, Y. Cohen, S. M. Dong, H. G. Klip, H. J. Buikema, A. J.H. Suurmeijer, H. Hollema, et al. Detecting Cervical Cancer by Quantitative Promoter Hypermethylation Assay on Cervical Scrapings: A Feasibility Study Mol. Cancer Res., May 1, 2004; 2(5): 289 - 295. [Abstract] [Full Text] [PDF]

				J. C. Lindsey, M. E. Lusher, J. A. Anderton, S. Bailey, R. J. Gilbertson, A. D.J. Pearson, D. W. Ellison, and S. C. Clifford Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling Carcinogenesis, May 1, 2004; 25(5): 661 - 668. [Abstract] [Full Text] [PDF]

				A. Widschwendter, H. M. Muller, H. Fiegl, L. Ivarsson, A. Wiedemair, E. Muller-Holzner, G. Goebel, C. Marth, and M. Widschwendter DNA Methylation in Serum and Tumors of Cervical Cancer Patients Clin. Cancer Res., January 15, 2004; 10(2): 565 - 571. [Abstract] [Full Text] [PDF]

				A. Rathi, A. K. Virmani, K. Harada, C. F. Timmons, K. Miyajima, R. J. Hay, D. Mastrangelo, A. Maitra, G. E. Tomlinson, and A. F. Gazdar Aberrant Methylation of the HIC1 Promoter Is a Frequent Event in Specific Pediatric Neoplasms Clin. Cancer Res., September 1, 2003; 9(10): 3674 - 3678. [Abstract] [Full Text] [PDF]

				S. Toyooka, K. O. Toyooka, K. Miyajima, J. L. Reddy, M. Toyota, U. G. Sathyanarayana, A. Padar, M. S. Tockman, S. Lam, N. Shivapurkar, et al. Epigenetic Down-Regulation of Death-associated Protein Kinase in Lung Cancers Clin. Cancer Res., August 1, 2003; 9(8): 3034 - 3041. [Abstract] [Full Text] [PDF]

				J. Yuan, R. Z. Luo, S. Fujii, L. Wang, W. Hu, M. Andreeff, Y. Pan, M. Kadota, M. Oshimura, A. A. Sahin, et al. Aberrant Methylation and Silencing of ARHI, an Imprinted Tumor Suppressor Gene in which the Function Is Lost in Breast Cancers Cancer Res., July 15, 2003; 63(14): 4174 - 4180. [Abstract] [Full Text] [PDF]

				S. S. Wang and A. Hildesheim Chapter 5: Viral and Host Factors in Human Papillomavirus Persistence and Progression J Natl Cancer Inst Monographs, June 1, 2003; 2003(31): 35 - 40. [Abstract] [Full Text] [PDF]

				B. Segura-Pacheco, C. Trejo-Becerril, E. Perez-Cardenas, L. Taja-Chayeb, I. Mariscal, A. Chavez, C. Acuna, A. M. Salazar, M. Lizano, and A. Duenas-Gonzalez Reactivation of Tumor Suppressor Genes by the Cardiovascular Drugs Hydralazine and Procainamide and Their Potential Use in Cancer Therapy Clin. Cancer Res., May 1, 2003; 9(5): 1596 - 1603. [Abstract] [Full Text] [PDF]

				I. Kuzmin, L. Liu, R. Dammann, L. Geil, E. J. Stanbridge, S. P. Wilczynski, M. I. Lerman, and G. P. Pfeifer Inactivation of RAS Association Domain Family 1A Gene in Cervical Carcinomas and the Role of Human Papillomavirus Infection Cancer Res., April 15, 2003; 63(8): 1888 - 1893. [Abstract] [Full Text] [PDF]

M.-Y. Yang, T.-C. Liu, J.-G. Chang, P.-M. Lin, and S.-F. Lin JunB gene expression is inactivated by methylation in chronic myeloid leukemia Blood, April 15, 2003; 101(8): 3205 - 3211. [Abstract] [Full Text] [PDF]